Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Resectable Hepatocellular Carcinoma × ADI PEG20 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2 Resectable Hepatocellular Carcinoma 1 Mesothelioma, Malignant 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Glioblastoma 1

Interventions

Nivolumab 1 ADI PEG20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04965714 2023-02-16

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Gastrointestinal

Resectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡